- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03218748
Honest, Open, Proud for Soldiers with Mental Illness
Adaptation and Evaluation of the Honest, Open, Proud Program for Soldiers with Mental Illness
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Soldiers with mental illness typically face a two-fold problem. On the one hand, they have to cope with the symptoms of their mental illness; on the other hand, they often have to deal with stigma and discrimination. Both due to fear of public stigma and due to self-stigma or shame, soldiers with mental illness may decide to keep their condition a secret or even to withdraw from other people altogether in order to minimize the risk of being labeled. Secrecy can help on the short term to protect individuals from public stigma, but usually it has negative long-term consequences such as social isolation, distress and avoidance of help-seeking. Disclosure, on the other hand, carries the risk to be discriminated by others, but can reduce the burden of secrecy, lead to support by others and reduce public stigma.
In this study investigators aim to test the efficacy (see our outcomes above) of Honest, Open, Proud run by soldiers with lived experience of mental illness.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10115
- Center for Military Mental Health
-
Ulm, Germany, 89073
- Department of Psychiatry II, Section Pubic Mental Health, Ulm University, Bezirkskrankenhaus Günzburg
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60616
- Illinois Institute of Technology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least one self-reported current axis I or axis II disorder according to DSM-5, which is not restricted to only substance-related disorder(s)
- Age 18 or above
- Ability to provide written informed consent
- Fluent in German (needed for self-report measures)
- At least a moderate level of self-reported disclosure-related distress/difficulty (score 4 or higher on the screening item 'In general, how distressed or worried are you in terms of secrecy or disclosure of your mental illness to others?', rated from 1, not at all, to 7, very much)
- Current inpatient, day-clinic or outpatient treatment at the Center for Military Mental Health, Berlin, Germany
- from April 2018 onwards we decided to also include non-military first responders (fire fighters or police officers) who are treated in the Center for Military Mental Health, Berlin, Germany
Exclusion Criteria:
- Self-reported diagnosis of only a substance- or alcohol-related disorder, without non-substance related current psychiatric comorbidity. We will exclude people who only have a substance-/alcohol-related disorder because the disclosure of these disorders is not the topic of the HOP intervention
- Intellectual disability
- Organic disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Honest, Open, Proud
The group program is about disclosure versus secrecy of one's mental illness. The groups are facilitated by two peers (soldiers with lived experience of mental illness). Each group runs for three weeks, one meeting per week, and two hours per meeting. There is one 2-hour booster session in week 6. Fidelity to manual: rated by a research assistant who is present during the group session |
Three lessons, one for each two-hour session plus one booster session
Other Names:
|
|
No Intervention: Control group
Treatment as usual (TAU)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stigma Stress Scale, 8 items
Time Frame: 3 weeks (T1)
|
(Rüsch et al. 2009a; Rüsch et al. 2009b)
|
3 weeks (T1)
|
|
WHOQoL BREF; Domain psychological quality of life, 6 items
Time Frame: 6 weeks (T2)
|
(WHOQoL Group 1998)
|
6 weeks (T2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Empowerment Scale, Subscale 'Self-esteem', 9 items
Time Frame: baseline, 3, 6 and 12 weeks (T3)
|
(Rogers et al. 1997)
|
baseline, 3, 6 and 12 weeks (T3)
|
|
Psychological Well-Being Scale, 18 items
Time Frame: baseline, 3, 6 and 12 weeks
|
(Ryff 1989)
|
baseline, 3, 6 and 12 weeks
|
|
Internalized Stigma of Mental Illness Inventory, Brief Version, 10 items
Time Frame: baseline, 3, 6 and 12 weeks
|
(Boyd et al. 2014)
|
baseline, 3, 6 and 12 weeks
|
|
Self-Stigma of Mental Illness Scale, Short Version, subscale Self-Concurrence, 5 items
Time Frame: baseline, 3, 6 and 12 weeks
|
(Corrigan et al. 2012)
|
baseline, 3, 6 and 12 weeks
|
|
Secrecy and Social Withdrawal subscales of the Stigma Coping Orientation Scales, 12 items
Time Frame: baseline, 3, 6 and 12 weeks
|
(Link et al. 1991)
|
baseline, 3, 6 and 12 weeks
|
|
Disclosure related distress ("In general, how distressed or worried are you in terms of secrecy or disclosure of your mental illness to others?', from 1, not at all, to 7, very much)
Time Frame: baseline, 3, 6 and 12 weeks
|
(Rüsch et al. 2014a)
|
baseline, 3, 6 and 12 weeks
|
|
WHOQoL-BREF, 26 items
Time Frame: 3, 6 and 12 weeks
|
(WHOQOL Group 1998)
|
3, 6 and 12 weeks
|
|
Patient Health Questionnaire (PHQ-9), 9 items
Time Frame: baseline, 3, 6 and 12 weeks
|
(Kroenke et al. 2001)
|
baseline, 3, 6 and 12 weeks
|
|
Shame about having a mental illness, 1 item
Time Frame: baseline, 3, 6 and 12 weeks
|
(Rüsch et al. 2014b)
|
baseline, 3, 6 and 12 weeks
|
|
Attitudes to help-seeking, 2 items
Time Frame: baseline, 3, 6 and 12 weeks
|
(Rüsch et al. 2013)
|
baseline, 3, 6 and 12 weeks
|
|
Attitudes to disclosure, 2 items
Time Frame: baseline, 3, 6 and 12 weeks
|
(Rüsch et al. 2011)
|
baseline, 3, 6 and 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nicolas Rüsch, Dr., Department of Psychiatry II, Section Public Mental Health, Ulm University, Bezirkskrankenhaus Günzburg
- Principal Investigator: Gerd-Dieter Willmund, Dr., Center for Military Mental Health, Berlin, Germany
- Principal Investigator: Peter Zimmermann, Dr., Center for Military Mental Health, Berlin, Germany
Publications and helpful links
General Publications
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
- Rogers ES, Chamberlin J, Ellison ML, Crean T. A consumer-constructed scale to measure empowerment among users of mental health services. Psychiatr Serv. 1997 Aug;48(8):1042-7. doi: 10.1176/ps.48.8.1042.
- Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998 May;28(3):551-8. doi: 10.1017/s0033291798006667.
- Rusch N, Corrigan PW, Wassel A, Michaels P, Olschewski M, Wilkniss S, Batia K. A stress-coping model of mental illness stigma: I. Predictors of cognitive stress appraisal. Schizophr Res. 2009 May;110(1-3):59-64. doi: 10.1016/j.schres.2009.01.006. Epub 2009 Mar 6.
- Corrigan PW, Michaels PJ, Vega E, Gause M, Watson AC, Rusch N. Self-stigma of mental illness scale--short form: reliability and validity. Psychiatry Res. 2012 Aug 30;199(1):65-9. doi: 10.1016/j.psychres.2012.04.009. Epub 2012 May 10.
- Boyd JE, Otilingam PG, Deforge BR. Brief version of the Internalized Stigma of Mental Illness (ISMI) scale: psychometric properties and relationship to depression, self esteem, recovery orientation, empowerment, and perceived devaluation and discrimination. Psychiatr Rehabil J. 2014 Mar;37(1):17-23. doi: 10.1037/prj0000035.
- Rusch N, Abbruzzese E, Hagedorn E, Hartenhauer D, Kaufmann I, Curschellas J, Ventling S, Zuaboni G, Bridler R, Olschewski M, Kawohl W, Rossler W, Kleim B, Corrigan PW. Efficacy of Coming Out Proud to reduce stigma's impact among people with mental illness: pilot randomised controlled trial. Br J Psychiatry. 2014;204(5):391-7. doi: 10.1192/bjp.bp.113.135772. Epub 2014 Jan 16.
- Link BG, Mirotznik J, Cullen FT. The effectiveness of stigma coping orientations: can negative consequences of mental illness labeling be avoided? J Health Soc Behav. 1991 Sep;32(3):302-20.
- Rusch N, Corrigan PW, Heekeren K, Theodoridou A, Dvorsky D, Metzler S, Muller M, Walitza S, Rossler W. Well-being among persons at risk of psychosis: the role of self-labeling, shame, and stigma stress. Psychiatr Serv. 2014 Apr 1;65(4):483-9. doi: 10.1176/appi.ps.201300169.
- Rusch N, Heekeren K, Theodoridou A, Dvorsky D, Muller M, Paust T, Corrigan PW, Walitza S, Rossler W. Attitudes towards help-seeking and stigma among young people at risk for psychosis. Psychiatry Res. 2013 Dec 30;210(3):1313-5. doi: 10.1016/j.psychres.2013.08.028. Epub 2013 Sep 4.
- Rusch N, Evans-Lacko SE, Henderson C, Flach C, Thornicroft G. Knowledge and attitudes as predictors of intentions to seek help for and disclose a mental illness. Psychiatr Serv. 2011 Jun;62(6):675-8. doi: 10.1176/ps.62.6.pss6206_0675.
- Rusch N, Corrigan PW, Powell K, Rajah A, Olschewski M, Wilkniss S, Batia K. A stress-coping model of mental illness stigma: II. Emotional stress responses, coping behavior and outcome. Schizophr Res. 2009 May;110(1-3):65-71. doi: 10.1016/j.schres.2009.01.005. Epub 2009 Feb 23.
- Ryff, C. D. (1989): Happiness is everything, or is it? Explorations on the meaning of psychological well-being. Journal of Personality and Social Psychology (57): 1069-1081.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HOP Soldiers
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Illness
-
Education University of Hong KongBaptist Oi Kwan Social ServiceCompletedSevere Mental IllnessHong Kong
-
New York UniversityUniversity of Pennsylvania; Yale UniversityCompleted
-
University of OklahomaCompleted
-
University of Illinois at ChicagoNational Institute on Disability, Independent Living, and Rehabilitation... and other collaboratorsCompletedMental Illness Persistent
-
Queen's UniversityCompletedSerious Mental Illness
-
McMaster UniversitySt. Joseph's Healthcare HamiltonNot yet recruitingSerious Mental IllnessCanada
-
Vrije Universiteit BrusselMondriaanNot yet recruitingMental Illness PersistentNetherlands
-
Temple UniversityRecruiting
-
Shalvata Mental Health CenterActive, not recruitingSevere Mental IllnessIsrael
-
King's College LondonSouth London and Maudsley NHS Foundation TrustCompletedSevere Mental IllnessUnited Kingdom
Clinical Trials on Honest, Open, Proud (HOP)
-
University of UlmIllinois Institute of Technology, Chicago, USA; Child and Adolescent Psychiatry... and other collaboratorsCompletedSecrecy Versus Disclosure Among Adolescents With Mental IllnessUnited States, Germany
-
Lakehead UniversityIllinois Institute of Technology, Chicago, USACompletedMental Health Issue | Stigmatization | DisclosureCanada
-
Oslo University HospitalUniversity of OsloRecruitingPsychotic Disorders | Bipolar Disorder | DisclosureNorway